- Home
- ALLO
as 04-01-2025 4:00pm EST
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 338.9M | IPO Year: | 2018 |
| Target Price: | $9.66 | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $4.30 | Next Earning Date: | 03-13-2025 |
| Revenue: | $22,000 | Revenue Growth: | -76.84% |
| Revenue Growth (this year): | 110.82% | Revenue Growth (next year): | -11.59% |
Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chang David D | ALLO | President and CEO | Mar 14 '25 | Sell | $1.96 | 46,668 | $91,469.28 | 5,276,569 | |
| Beneski Benjamin Machinas | ALLO | SVP, Chief Technical Officer | Mar 14 '25 | Sell | $1.98 | 5,488 | $10,838.80 | 218,507 | |
| MESSEMER DEBORAH M. | ALLO | Director | Feb 18 '25 | Sell | $2.43 | 13,313 | $32,350.59 | 144,316 | |
| Douglas Earl Martin | ALLO | SVP, General Counsel | Feb 3 '25 | Sell | $1.71 | 6,404 | $10,950.84 | 587,848 | |
| Parker Geoffrey M. | ALLO | CHIEF FINANCIAL OFFICER | Feb 3 '25 | Sell | $1.73 | 4,361 | $7,544.53 | 1,301,540 | |
| Chang David D | ALLO | President and CEO | Feb 3 '25 | Sell | $1.68 | 46,003 | $77,285.04 | 5,276,569 | |
| MOORE TIMOTHY L. | ALLO | Chief Technical Officer | Feb 3 '25 | Sell | $1.71 | 14,746 | $25,215.66 | 250,713 | |
| Roberts Zachary | ALLO | EVP of R&D | Feb 3 '25 | Sell | $1.70 | 18,832 | $32,014.40 | 643,135 | |
| Roberts Zachary | ALLO | EVP of R&D | Jan 21 '25 | Sell | $1.78 | 27,199 | $48,414.22 | 643,135 |
Latest Allogene Therapeutics Inc. News
ALLO Breaking Stock News: Dive into ALLO Ticker-Specific Updates for Smart Investing
Simply Wall St.
18 days ago
Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
19 days ago
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ...
Zacks
19 days ago
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
Associated Press Finance
20 days ago
Allogene Therapeutics: Q4 Earnings Snapshot
GlobeNewswire
20 days ago
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
GlobeNewswire
a month ago
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
GlobeNewswire
a month ago
Allogene Therapeutics Announces Participation in March Investor Conference
GlobeNewswire
a month ago
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
Compare ALLO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLO Allogene Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.